Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20334431 | 0.81 | CES2 (0.48) | EGFRPAX8ABL1FFAR3ALDH1A1 | |
| SCHEMBL2282136 | 0.76 | EGFR (0.46) | EGFRPAX8ABL1HSD17B10FFAR3 | |
| SCHEMBL8892110 | 0.76 | TDP1 (0.35) | EGFRTDP1FFAR3ALDH1A1 | |
| SCHEMBL9517162 | 0.75 | — | — | |
| SCHEMBL15010306 | 0.75 | EGFR (0.44) | EGFRPAX8ABL1 | |
| SCHEMBL23735948 | 0.75 | CA12 (0.37) | TDP1 | |
| SCHEMBL17773344 | 0.75 | EGFR (0.40) | EGFRPAX8ABL1 | |
| SCHEMBL164434 | 0.74 | — | — | |
| SCHEMBL25144748 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL20699298 | 0.72 | EGFR (0.53) | EGFRPAX8ABL1HSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | ERASCA, INC. | 2021-09-23 | — | — | US | disclosed |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | AMGEN INC. (US) | 2018-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292330-A1 | PYRROLIDINE-FUSED HETEROCYCLES | SDHB, CCNI, SDHA | EGFR 2973/4885PAX8 1105/4885ABL1 534/4885 |
| US-20180177767-A1 | KRAS G12C INHIBITORS AND METHODS OF USING THE SAME | KRAS, NRAS, HRAS | EGFR 142/4885PAX8 1282/4885ABL1 391/4885 |
| US-10538513-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | EGFR 864/4885PAX8 4264/4885ABL1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.